The Economics of Biologic Drugs
The market for biologic drugs in the United States is large and growing. Total US biologic sales in 2018 is estimated to have been $125 billion, an increase of 50 percent since 2014.
Biologics are Not Natural Monopolies
Recently, several physicians and health policy analysts took to the Health Affairs blog to propose what was, to anyone who has been following biosimilars for the last decade or more, a surprising and concerning idea: that biosimilars should be abandoned.
2018 Charitable Giving Dips, as Predicted
A Giving USA report released last week shows that US households’ charitable donations in 2018 experienced the largest decline since the Great Recession. We hate to say we told you so, but we told you so.
Action on Climate Change Should Not Include Creation of New Entitlements
Over the last two years, the United States has scaled back Obama-era climate change policies, withdrawing from the Paris Agreement and rolling back climate-related regulations.
Carbon Tax Most Efficient in Tackling Climate Change
It is encouraging to see more and more fellow Republicans shed the reflexive skepticism about climate change that has characterized the GOP for years. Now, Republicans need to offer solutions.
Costs of the Green New Deal
With the government reopened (at least for now), Speaker Nancy Pelosi is poised to begin advancing her party’s policy agenda. High on the list will be the loosely-defined Green New Deal, a federal spending program that will cost $2 trillion, $5.7 trillion, or more, and move the electric power sector to complete reliance on renewable energy sources.
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
- A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax Reform
